NASDAQ: OCEAOcean Biomedical Inc Stock
$0.04+0.00 (+0%)
Updated Apr 21, 2025
Ocean Biomedical shares are trading... find out Why OCEA Price Moved with a free WallStreetZen account
Why Price MovedOCEA Price
$0.04
Fair Value Price
N/A
Market Cap
$6.64M
52 Week Low
$0.04
52 Week High
$2.09
P/E
-0.12x
P/B
-0.07x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$9.48M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-1.01
Operating Cash Flow
-$4M
Beta
0.47
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
OCEA Overview
Aesther Healthcare Acquisition Corp. is a "blank check" company formed to effect mergers, share exchanges, asset acquisitions, share purchases, reorganizations, or similar combinations with one or more businesses. The company targets the pharmaceutical and medical devices sectors. Aesther was incorporated in 2021 and is based in New York, NY.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine OCEA's potential to beat the market
- OCEA doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
OCEA
RankedUnranked of 462
RankedUnranked of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.55 | A | |
| $7.66 | A | |
| $22.02 | A |
Be the first to know about important OCEA news, forecast changes, insider trades & much more!
OCEA News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how OCEA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
OCEA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
OCEA is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
OCEA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more OCEA due diligence checks available for Premium users.
Valuation
OCEA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.12x
Industry
-184.27x
Market
27.14x
OCEA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.07x
Industry
4.04x
OCEA's financial health
Profit margin
Revenue
$0.0
Net Income
$283.0k
Profit Margin
0%
OCEA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$902.0k
Liabilities
$98.5M
Debt to equity
-1.01
OCEA's short-term liabilities ($33.89M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
OCEA's long-term liabilities ($64.63M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
OCEA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
OCEA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.5M
Investing
$0.0
Financing
$2.5M
OCEA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
OCEA vs Biotech Stocks
Ocean Biomedical Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.